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Abstract
Aims The prevalence of hepatic steatosis may differ between post-menopausal African-American women and non-
Hispanic white women and by sex hormone binding globulin level. We examined prevalence of hepatic steatosis by race/
ethnicity and associations with sex hormone binding globulin.
Methods Participants included post-menopausal women who underwent hepatic ultrasound (n = 345) at the
Michigan site of the Study of Women’s Health Across the Nation, a population-based study. We examined hepatic
steatosis prevalence by race/ethnicity and used logistic regression models to calculate the odds of hepatic steatosis with
race/ethnicity and sex hormone binding globulin, after adjustment for age, alcohol use, waist circumference, high
density lipoprotein cholesterol, triglycerides, systolic blood pressure and use of medications reported to lower
intrahepatic fat.
Results Fewer African-American women than non-Hispanic white women had hepatic steatosis (23 vs. 36%,
P = 0.01). African-American women had lower triglyceride and low-density lipoprotein cholesterol levels, but higher
blood pressure and follicle-stimulating hormone levels (P < 0.05). In the optimal-fitting multivariable models, women in
the highest tertile of sex hormone binding globulin (60.2–220.3 nmol/l) had a lower odds of hepatic steatosis (odds
ratio 0.43, 95% CI 0.20–0.93) compared with women in the lowest tertile of sex hormone binding globulin (10.5–
40.3 nmol/l). There was an interaction between race/ethnicity and medication use whereby non-Hispanic white women
using medications had three times higher odds of hepatic steatosis compared with African-American women not using
medications (odds ratio 3.36, 95% CI 1.07–10.58). Interactions between race/ethnicity and other variables, including
sex hormone levels, were not significant.
Conclusions Hepatic steatosis on ultrasound may be more common in post-menopausal non-Hispanic white women
than African-American women and was associated with lower levels of sex hormone binding globulin.
Diabet. Med. 30: 1433–1441 (2013)
Introduction
The relationship between non-alcoholic fatty liver disease,
also known as non-alcoholic hepatic steatosis, and glucose
tolerance is complex. Insulin resistance is a well-recognized
risk factor for hepatic steatosis [1], yet hepatic steatosis may
also be a risk factor for incident diabetes, independent of
traditional diabetes risk factors including age, body shape
and size and insulin levels [2]. One potential mechanism
relating hepatic steatosis and peripheral glucose is sex
hormone binding globulin (SHBG), a glycoprotein manufac-
tured primarily by the liver, whose production may be
impaired in the presence of hepatic steatosis [3]. SHBG might
lead to decreased hepatic gluconeogenesis apart from hepatic
steatosis, as SHBG and fasting glucose are still significantly
associated after adjustment for liver fat [3], although a study
in men did not find this [4].
No population-based studies have examined the relation-
ship between SHBG and the presence of hepatic steatosis in
post-menopausal women. Post-menopausal status comparedCorrespondence to: Catherine Kim. E-mail: cathkim@umich.edu
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with pre-menopausal status has been associated with an
almost twofold increase in odds, after adjustment for age
[5,6], and, in Koreans, the prevalence of hepatic steatosis in
post-menopausal Asian women is 24–28% compared with
6–8% in pre-menopausal women [5]. The menopausal
transition is characterized by declines in SHBG and oestra-
diol and increases in relative androgenicity [7], suggesting
that SHBG could contribute to the higher prevalence in post-
menopausal women. Moreover, the menopausal transition
has been associated with a worsening profile of the compo-
nents of the metabolic syndrome, particularly lipid profiles
[8], which are also risk factors for hepatic steatosis [9,10].
Among women, it is also possible that the relationship
between sex hormones and hepatic steatosis differs between
non-Hispanic white women and African-American women.
Studies conflict regarding racial/ethnic differences in sex
hormone profiles [11–14], as well as regarding the prevalence
of hepatic steatosis in non-Hispanic white subjects and
African-American women [15,16].
Taken together, these studies suggest that SHBG and the
sex steroids that it binds might contribute both to hepatic
steatosis and to racial/ethnic differences in hepatic steatosis
among women. The Study of Women’s Health Across the
Nation (SWAN) is an ongoing population-based cohort
study designed to characterize biological and symptomatic
changes that occur during and after menopause among
women of different racial/ethnic backgrounds [17]. The
Michigan Study of Women’s Health Across the Nation site
ascertained hepatic steatosis with ultrasound, the most
common imaging technique in clinical practice, at the 2010
annual follow-up visit, when participants were post-men-
opausal. Thus, we were able to examine the prevalence of
hepatic steatosis in post-menopausal African-American
women and non-Hispanic white women and evaluate the
contribution of sex hormone profile to hepatic steatosis.
We hypothesized that non-Hispanic white women would
more frequently have hepatic steatosis than African-
American women. We also hypothesized that lower SHBG
would be associated with increased prevalence of hepatic
steatosis.
Patients and methods
Study population
The sample was drawn from the Michigan site of the Study
of Women’s Health Across the Nation cohort. Recruitment
procedures and the study design used have been described
elsewhere [17–19]. Briefly, in 1996–1997, women aged 40–
55 years were screened from defined sampling frames at
seven clinical sites throughout the USA. Eligible women were
invited to participate in a longitudinal study of the natural
history of the menopausal transition. To be eligible, women
had to be between 42 and 52 years of age, have an intact
uterus and at least one ovary, to report having had a
menstrual period in the previous 3 months, to not report
oestrogen therapy in the 3 months prior to recruitment, and
not currently be pregnant or breastfeeding. All participants
gave informed consent and all study procedures were
approved by the University of Michigan institutional review
board.
The Michigan site recruited women who self-identified as
being African-American or non-Hispanic white. At the time
of their 2010 follow-up visit, 345 (85%) of the 406 women
from the study who participated underwent hepatic ultra-
sound. Women who did not undergo ultrasound had higher
SHBG than women who underwent ultrasound (66.3 vs.
49.8 nM/l, P < 0.05). Women who did not have ultraounds
were otherwise similar. Of the women with hepatic ultra-
sound measures, 14 women reported a history of cirrhosis or
chronic liver disease attributable to viral hepatitis or hema-
chromatosis and were excluded, leaving a total analytic
sample of 331 participants for this report.
Data collection
The Study of Women’s Health Across the Nation protocol
includes annual questionnaires, anthropometrics, blood
pressure assessments and serum measures. Women were
defined as post-menopausal if they had no menses for 12 or
more months. Information regarding use of medications
reported to influence hepatic adiposity (including metformin,
thiazolidinediones, orlistat or sibutramine) was obtained, as
was exogenous oestrogen therapy. Oestrogen therapy was
characterized as length of oestrogen therapy use and also as
‘ever use’ vs. ‘never use’. No women used sibutramine and
only one woman used orlistat.
Phlebotomy was performed in the morning after an
overnight fast, blood was refrigerated 1–2 h after phlebot-
omy and after centrifugation, and the serum was aliquotted
and frozen. Serum was stored at –70 °C. Insulin was
measured in serum by solid phase radioimmunoassay
(Coat-A-Count; Diagnostics Product Corp., Los Angeles,
CA, USA) and glucose was measured using a hexokinase-
coupled reaction (Roche Molecular Biochemicals Diagnos-
tics, Indianapolis, IN, USA). Insulin resistance was estimated
What’s new?
• Although hepatic steatosis is common in post-meno-
pausal women, previous studies have not examined
risk factors in this population, particularly sex steroids
and sex hormone binding globulin.
• We report that increased sex hormone binding globulin,
the primary binding protein of sex hormones and a risk
factor for diabetes, was strongly associated with
decreased odds of hepatic steatosis in both race/ethnic-
ities.
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using the homeostasis model assessment of insulin resistance
(HOMA-IR), defined as [fasting insulin 9 (fasting glucose/
18.01)/22.5] [20]. Total cholesterol and triglycerides were
analysed by enzymatic methods and high density lipoprotein
(HDL) cholesterol was isolated after addition of heparin
and 2 mol/l manganese(II) chloride (MnCl2). Low density
lipoprotein (LDL) cholesterol was calculated using the
Friedewald equation. HbA1c was determined on a Tosoh
G7 HPLC Analyzer (Tosoh Biosciences Inc., South San
Francisco, CA, USA).
SHBG was a de novo two-site chemiluminescent assay
(inter- and intra-assay coefficients of variation were 9.9 and
6.1%, respectively). Serum follicle stimulating hormone con-
centrationsweremeasuredwith a two-site chemiluminometric
immunoassay (inter- and intra-assay coefficients of variation
were 12.0 and 6.0%, respectively). Oestradiol and testoster-
one assayswere conducted in theUniversity ofMichigan Study
of Women’s Health Across the Nation Endocrine Laboratory
using the ACS-180 automated analyser (Bayer Diagnostics
Corp., Norwood,MA,USA). Serumoestradiol concentrations
were measured with a modified, off-line ACS:180 (oestradiol-
6) immunoassay (inter- and intra-assay coefficients of
variation were 10.6 and 6.4%, respectively). Testosterone
concentrations were evaluated with the ACS:180 total testos-
terone assay, modified to increase precision in the low ranges
(inter- and intra-assay coefficients of variation were 10.5 and
8.5%, respectively). Total testosterone was indexed to SHBG
to calculate the free androgen index as the measure of relative
androgenicity [free androgen index = 100 9 testosterone
(ng/dl)/28.84 9 SHBG (nM)] [21].
All abdominal ultrasounds were performed by a single
ultrasound technician unaware of the clinical and laboratory
results of the participants, on a Sonoline Elegra Ultrasound
Imaging System (Siemens Medical Systems Inc., Delaware,
WA, USA), using a 3.5-MHz transducer, a phantom (411 LE
0.5; Gammex RMI Ltd., Nottingham, UK) and also read by
a radiologist who was blinded to participant profile. Ultra-
sound studies were performed and classified according to the
protocol of the Edinburgh Type 2 Diabetes Study [22]. The
liver was graded for markers of hepatic steatosis including
bright hepatic echo pattern compared with the echo response
of the right kidney, attenuation of the echo beam and
presence of focal fatty sparing. In the Edinburgh cohort [22],
validation in a subset with 1H magnetic resonance spectros-
copy noted that moderate and severe hepatic steatosis on
ultrasound was associated with magnetic resonance spec-
troscopy hepatic fat fraction ≥ 6.1% in all cases, while less
severe hepatic steatosis overlapped significantly with absence
of hepatic steatosis with respect to magnetic resonance
spectroscopy fat fraction. We performed preliminary analy-
ses in our population and found that women with no hepatic
steatosis and mild hepatic steatosis did not differ regarding
the variables noted in Table 1, therefore in this report we
compare women with no/mild hepatic steatosis with women
with moderate/severe hepatic steatosis.
Statistical analysis
First, we examined race/ethnic differences in demographic,
health history, cardiometabolic biomarkers and sex hormones
using t-tests forcontinuousvariablesandv2-tests forcategorical
variables. Log-transformations were employed for continuous
variableswith skewed distributions, i.e. insulin, triglyceride and
sex hormones; the log-transformed levels were compared and
back-transformed for presentation. SHBG was examined as a
continuous variable and as categorical tertiles in the absence of
established cut points for SHBG. Next, we examined the
unadjusted associations between each variable with the pres-
enceofhepaticsteatosis for the overall study population and by
race/ethnicity. Because of previous reports noting that
hepatic steatosis differed between African-American women
and non-Hispanic white subjects [15], interactions were
evaluated between race/ethnicity and other variables includ-
ing sex hormones and metabolic markers; interactions were
only significant for race/ethnicity and medication use and
thus was evaluated for inclusion in multivariate models.
Variables that were associated with hepatic steatosis in the
literature or in the bivariate analyses were considered for
inclusion in multivariable models. Variables known to be
collinear (i.e. diabetes status, insulin, glucose, use of metfor-
min and thiazolidinediones) were not considered in the same
model. We examined use of metformin and thiazolidinedi-
ones, as reports have noted that these medications are
associated with lower hepatic steatosis [23,24], as opposed to
other hypoglycaemic medications such as sulphonylureas or
insulin [24]. Although we only had a single measure of
hepatic steatosis obtained at the 12th year of follow-up, we
attempted to capture prospective relationships and specifi-
cally risk factors obtained before the menopausal transition
by examining baseline levels of covariates as well as
covariates at year 12. We created separate models containing
baseline and year 12 levels as these values were highly
collinear. Year 12 variables had stronger associations with
hepatic steatosis than baseline levels for all risk factors, so
year 12 data are presented. Beause of limited sample size, the
best fit in the model was selected based on the Akaike
information criterion (AIC), whereby the model with the
smallest Akaike information criterion was selected [25]. In a
sensitivity analysis, we excluded the few women who
reported two or more alcoholic beverages per day, but the
pattern of results was similar, so associations are reported for
all of the Study of Women’s Health Across the Nation
women who underwent ultrasound. All analyses were
conducted using SAS version 9.3 (SAS Institute, Cary, NC,
USA).
Results
Thirty-six-per cent (n = 47) of non-Hispanic white women
and 23% (n = 47) of African-American women had hepatic
steatosis. Table 1 shows the distribution of risk factors among
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non-Hispanic white women and African-American women
who underwent ultrasound. Only eight non-Hispanic white
women and four African-American women reported two or
more alcoholic beverages per day. Non-Hispanic white
women had higher triglycerides and LDL cholesterol than
African-American women, while African-American women
had higher systolic and diastolic blood pressure than non-
Hispanic white women. For the sex hormones, only follicle
stimulating hormone differed by race/ethnicity. Table 2
shows the distribution of risk factors by hepatic steatosis
status. Non-Hispanic white race/ethnicity, alcohol intake, use
of medications and oestrogen therapy were associated with
hepatic steatosis. Greater waist circumference, body mass
index (BMI), fasting glucose, insulin, HOMA-IR, triglyceride
and lower HDL were also associated with hepatic steatosis,
but blood pressure was not. Lower SHBG and follicle
stimulating hormone and greater free androgen index were
associated with hepatic steatosis, but oestradiol and testos-
terone were not. Seventeen per cent of women usedmetformin
(n = 56) and 2% used pioglitazone (n = 7); all of the
pioglitazone users were metformin users also.
The pattern of associations between risk factors shown in
Table 2 and hepatic steatosis was generally similar among
African-American women and non-Hispanic white women,
with one notable exception. Use of metformin and thiazo-
lidinediones was associated with increased hepatic steatosis
in non-Hispanic white women, but not among African-
American women; African-American women who used
metformin and thiazolidinediones had the lowest prevalence
of hepatic steatosis (19%) and non-Hispanic white women
who used medications had the highest (71%) (Fig. 1). HbA1c
values were highest among non-Hispanic white women using
medications [64  1 mmol/mol (8.0  2.2%)] compared
with non-Hispanic white women not using medications
[40  1 mmol/mol (5.8  0.8%)], African-American
women using medications [53  1 mmol/mol
(7.0  1.2%)] and African-American women not using med-
ications [42  13 mmol/mol (6.0  1.0%)].
In the optimal-fitting multivariable model (Table 3),
higher SHBG values were associated with decreased odds
of hepatic steatosis; women in the highest SHBG tertile
(60.2–220.3 nM/l) had nearly a 60% reduction in their odds
of hepatic steatosis compared with women in the lowest
tertile (10.5–40.3 nM/l). There was a statistically significant
decreasing trend in odds of hepatic steatosis corresponding to
increasing SHBG tertiles. Greater waist circumference was
associated with increased odds of hepatic steatosis (odds
ratio 1.03, 95% CI 1.01–1.05). Women with a waist
Table 1 Characteristics of 331 women who underwent hepatic ultrasound at 2010 follow-up visit by race/ethnicity
African-American women
(n = 201)
Non-Hispanic white
women (n = 130) P-value
Hepatic steatosis 47 (23.4%) 47 (36.2%) 0.01
Demographic characteristics and medical history
Age (years) 59.4 (0.2) 59.9 (0.2) 0.10
Years since final menstrual period 7.9 (0.3) 7.8 (0.3) 0.77
Number of alcoholic beverages/day
< 1 137 (68.2%) 77 (59.2%) 0.17
1 56 (27.9%) 49 (37.7%)
2 or more 8 (4.0%) 4 (3.1%)
Diagnosed diabetes 50 (24.9%) 27 (20.8%) 0.39
Medication use 31 (15.4%) 21 (16.2%) 0.86
Oestrogen therapy (ever/never) 16 (8.0%) 14 (10.8%) 0.39
Cardiometabolic biomarkers
Waist circumference (cm) 101.1 (1.2) 101.3 (1.5) 0.93
BMI (kg/m2) 34.3 (0.6) 34.0 (0.8) 0.70
Fasting glucose (mmol/l) 5.71 (0.16) 6.09 (0.30) 0.22
Fasting insulin (pmol/l) 124.3 (11.8) 116.7 (11.8) 0.65
Homeostasis model assessment of insulin resistance 4.9 (0.47) 4.9 (0.67) 0.97
Triglycerides (mmol/l) 1.26 (0.04) 1.55 (0.08) < 0.01
HDL cholesterol (mmol/l) 1.44 (0.03) 1.49 (0.03) 0.34
LDL cholesterol (mmol/l) 2.96 (0.06) 3.17 (0.08) 0.045
Systolic blood pressure (mmHg) 133.6 (1.4) 123.9 (1.6) < 0.01
Diastolic blood pressure (mmHg) 75.5 (0.8) 70.6 (0.8) < 0.01
Sex hormones
Sex hormone binding globulin (nM/l)
Tertile 1: 10.5–40.3 (nM/l) 69 (34.2%) 48 (36.9%) 0.29
Tertile 2: 40.5–59.5 (nM/l) 72 (35.8%) 60 (46.2%)
Tertile 3: 60.2–220.3 (nM/l) 60 (29.9%) 46 (35.4%)
Testosterone (nmol/l) 1.85 (0.05) 1.79 (0.07) 0.43
Oestradiol (pmol/l) 92.5 (5.5) 107.9 (16.2) 0.32
Follicle stimulating hormone (IU/l) 52.4 (1.9) 58.6 (2.4) 0.04
Free androgen index 122.6 (6.0) 120.3 (7.2) 0.81
Means (SE) or n (%) shown.
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circumference at the 75th percentile had 70% increased odds
of hepatic steatosis as compared with women with a waist
circumference at the 25th percentile. Of note, we also
evaluated models containing other variables that were
significant in bivariate analyses, including oestrogen therapy
and the free androgen index. These models had poorer fit
using Akaike information criterion criteria than those
including the variables in Table 3. Compared with African-
Table 2 Characteristics of 331 women who underwent hepatic ultrasound at 2010 follow-up visit by hepatic steatosis status
No hepatic steatosis
(n = 237)
Hepatic steatosis
(n = 94) P-value
Demographic characteristics and medical history
Non-Hispanic white women 83 (35.0%) 47 (50.0%) 0.01
Age (years) 59.4 (0.2) 60.0 (0.3) 0.07
Years since final menstrual period 7.6 (0.3) 8.5 (0.4) 0.08
Number of alcoholic beverages/day
< 1 143 (60.3%) 71 (75.5%) 0.04
1 84 (35.4%) 21 (22.34%)
2 or more 10 (4.2%) 2 (2.1%)
Diagnosed diabetes 49 (20.7%) 28 (29.8%) 0.08
Medication use (metformin, thiazolidinediones, orlistat) 31 (13.1%) 21 (22.3%) 0.04
Oestrogen therapy (ever/never) 27 (11.4%) 3 (3.2%) 0.03
Cardiometabolic biomarkers
Waist circumference (cm) 97.3 (1.1) 110.8 (1.5) < 0.01
BMI (kg/m2) 32.7 (0.5) 37.8 (0.8) < 0.01
Fasting glucose (mmol/l) 5.38 (0.11) 7.06 (0.42) < 0.01
Fasting insulin (pmol/l) 94.5 (9.03) 188.2 (18.8) < 0.01
Homeostasis model assessment of insulin resistance 3.6 (0.4) 8.4 (0.9) < 0.01
Triglycerides (mmol/l) 1.25 (0.04) 1.68 (0.10) < 0.01
HDL cholesterol (mmol/l) 1.52 (0.03) 1.31 (0.04) < 0.01
LDL cholesterol (mmol/l) 3.05 (0.06) 3.01 (0.09) 0.67
Systolic blood pressure (mmHg) 128.9 (1.2) 131.9 (2.1) 0.21
Diastolic blood pressure (mmHg) 73.9 (0.7) 72.9 (1.1) 0.46
Sex hormones
Sex hormone binding globulin (nM/l)
Tertile 1: 10.5–40.3 (nM/l) 67 (28.3%) 50 (53.2%) < 0.01
Tertile 2: 40.5–59.5 (nM/l) 79 (33.3%) 29 (30.9%)
Tertile 3: 60.2–220.3(nM/l) 91 (38.4%) 15 (16.0%)
Testosterone (mmol/l) 1.79 (0.05) 1.92 (0.07) 0.15
Oestradiol (pmol/l) 97.6 (9.54) 99.9 (5.5) 0.88
Follicle stimulating hormone (IU/l) 58.4 (1.8) 45.9 (2.2) < 0.01
Free androgen index 107.9 (4.6) 155.8 (10.5) < 0.01
Means (SE) or n (%) shown.
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FIGURE 1 Unadjusted prevalence of hepatic steatosis in non-Hispanic white women and African-American women by use of medications reported to
decrease hepatic adiposity.
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American women not using medications, non-Hispanic white
women using medications had more than three times greater
odds of hepatic steatosis (odds ratio 3.36, 95% CI
1.07–10.58), whereas no differences were observed for
non-Hispanic white women not using medications or
African-American women using medications (Table 3). We
also examined how the relationship between SHBG and
hepatic steatosis was altered by other risk factors for hepatic
steatosis (BMI, waist circumference, lipid subfractions,
HOMA-IR) and whether this relationship differed by race/
ethnicity, diabetes status or use of diabetic medication. In all
of these subgroups, higher SHBG levels were still signifi-
cantly and strongly associated with hepatic steatosis and
were not markedly reduced by consideration of BMI or waist
circumference (results not shown). We also examined the
subgroups of women without diabetes, women using met-
formin and thiazolidinediones, and women with diabetes but
not using metformin or thiazoldinediones, and found a
similar pattern of associations. (results not shown).
Discussion
In a community-based cohort of post-menopausal women,
we found that hepatic steatosis, a strong risk factor for
diabetes, was common on ultrasound. Nearly one quarter of
African-American women and just over one third of non-
Hispanic white women were affected. Increased SHBG, the
primary binding protein of sex hormones and a risk factor
for diabetes, was strongly associated with decreased odds of
hepatic steatosis in both African-American women and non-
Hispanic white women.
One explanation for these findings is that SHBG is
manufactured by the liver, and it is possible that steatotic
livers produce less SHBG, and that SHBG and hepatic
steatosis have a common antecedent such as visceral adipos-
ity or insulin resistance [3]. Among pre-menopausal women
with polycystic ovarian syndrome, SHBG has been associated
with mesenteric fat thickness [26] and mesenteric fat (which
drains into the portal circulation) and was more strongly
associated with fatty liver than anthropometric measures of
fat or preperitoneal fat [26]. Also among women with
polycystic ovarian syndrome, SHBG is associated with
hepatic steatosis even after adjustment for visceral steatosis
[27]. Among approximately 155 pre- and post-menopausal
Korean women, lower SHBG was associated with hepatic
steatosis on ultrasound after adjustment for waist circum-
ference, hypoglycaemic medications and fasting glucose and
insulin [28]. However, a report in men did not find that
SHBG correlated with intrahepatic fat or hepatokines (fet-
uin A and FGF21) [4], even as SHBG correlated with
peripheral glucose. Therefore, it is also possible that SHBG
is associated with hepatic steatosis, particularly in the setting
of elevated glucose, and a significant proportion of women in
our study had adverse metabolic profiles, or it is also possible
that the association between SHBG and hepatic steatosis
differs between women and men.
Two other population-based studies of hepatic steatosis
prevalence among women conflict regarding racial/ethnic
differences. The Dallas Heart Study reported that non-
Hispanic white women and African-American women had a
similar prevalence of hepatic steatosis [29]. In contrast, the
National Heart, Lung, and Blood Institute (NHLBI) Family
Heart Study reported that non-Hispanic white women had a
greater prevalence of hepatic steatosis than African-American
women [16]. Our participants were approximately 60 years
of age, NHLBI Family Heart Study participants were approx-
imately 56 years of age and Dallas Heart Study participants
were approximately 47 years of age. Therefore it is possible
that greater racial/ethnic differences in hepatic steatosis exist
primarily among older, post-menopausal women. Although
we had also hypothesized that racial/ethnic differences might
be at least partially explained by racial/ethnic differences in
sex steroids post-menopause, adjustment for SHBG and also
adjusting for oestrogen therapy did not explain the association
between race/ethnicity and hepatic steatosis (data not shown)
and the inclusion of oestrogen therapy and sex steroids in
multivariate models did not improve model fit.
As in other population-based reports [16,29], African-
American women in the Michigan Study of Women’s Health
Across the Nation had lower triglycerides than non-Hispanic
white women, consistent with racial/ethnic differences in
fatty acid metabolism and hepatic triglyceride deposition
[30]. A genetic variant of PNPLA3 [rs6006460(T)] has been
associated with lower hepatic fat among African-American
women, while the PNPLA3 rs738409 G susceptibility allele
has been associated with hepatic steatosis among non-
Table 3 Multivariable adjusted model for hepatic steatosis among
participants in the Michigan Study of Women’s Health Across the
Nation
Characteristic
Adjusted odds ratio,
95% confidence
interval
Age (years) 1.12 (1.01–1.23)
African-American women with no
metformin/thiazolidinedione use
Reference
African-American women with
metformin/thiazolidinedione use
0.41 (0.14–1.15)
Non-Hispanic white women with
no metformin/thiazolidinedione use
1.41 (0.76–2.64)
Non-Hispanic white women with
metformin/thiazolidinedione use
3.36 (1.07–10.58)
Waist circumference (cm) 1.03 (1.01–1.05)
HDL cholesterol (mmol/l) 0.99 (0.96–1.01)
Triglycerides (mmol/l) 1.00 (0.99–1.01)
Alcoholic drinks per day
< 1 Reference
1 or more 0.58 (0.31–1.07)
Sex hormone binding globulin (nM/l)
Tertile 1: 10.5–40.3 (nM/l) Reference
Tertile 2: 40.5–59.5 (nM/l) 0.64 (0.34–1.22)
Tertile 3: 60.2–220.3 (nM/l) 0.42 (0.19–0.91)
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Hispanic white women [31,32]. Unlike other variants,
PNPLA3 does not affect any other metabolic traits, but
may increase hepatic steatosis by preventing hepatic break-
down of triglycerides [32]. While the association is strong,
not all persons with the susceptibility alleles have hepatic
steatosis, despite the additional presence of adverse risk
factors such as obesity [32]. To our knowledge, interactions
between these polymorphisms and medication effectiveness
have not been examined. Medications previously reported to
reduce hepatic adiposity, particularly the hypoglycaemic
medications of metformin and thiazolidinediones, were
associated with increased odds of hepatic steatosis in non-
Hispanic white women, but not in African-American
women. Medication use may have been a proxy for greater
insulin resistance, as HbA1c values were higher among
women using medications than among women not using
medications. Medications, combined with other factors in
the model such as SHBG, waist circumference, and race/
ethnicity, captured a greater proportion of variance than
models with insulin resistance, perhaps because medication
prescription may also capture other steatosis risk factors such
as inflammation [33]. However, it is unclear why the
association between medication use and greater prevalence
of hepatic steatosis would be stronger in non-Hispanic white
women than in African-American women. Although we did
not find racial/ethnic differences in self-reported use of
medications, medications may interact with other risk factors
that do differ by race/ethnicity, such as triglycerides or these
polymorphisms [34].
Our study has several strengths. We examined a well-
characterized population-based cohort of women using a
measure of hepatic steatosis that is commonly used in clinical
practice and may be applied in large-scale epidemiologic
studies. Unlike other epidemiologic studies of hepatic stea-
tosis among diverse samples of women, the African-Amer-
ican women and non-Hispanic white women in our
population were similar with respect to known risk factors
for hepatic steatosis, thereby reducing the likelihood of
confounding by these measures. The Michigan Study of
Women’s Health Across the Nation population includes
excellent ascertainment of known risk factors, including
health history, cardiometabolic biomarkers and sex hormone
values not available in other studies. Limitations of our study
include the lack of biopsy for confirmation, as this is
logistically challenging for epidemiologic studies, and lack
of transaminases as a peripheral marker of inflammation. We
note that the spectrum of hepatic steatosis includes non-
alcoholic steatotic hepatitis, but also includes more benign
fatty liver disease, and thus we cannot comment about the
severity of inflammation or scarring. While models examin-
ing risk factors measured from a decade previously did not
reveal a different pattern of associations, we only had a single
measure of hepatic steatosis. Thus, our analysis was cross-
sectional and we could not determine causality. We did not
have measures of visceral adiposity or insulin sensitivity based
on clamp studies. Finally, the greater prevalence of hepatic
steatosis in the women in the Michigan Study of Women’s
Health Across the Nation as compared with other cohort
studies could reflect unique characteristics of the geographical
area. Of note, the Dallas study recruited from Dallas County,
Texas and the NHLBI study enrolled participants from the
Framingham Heart Study cohort as well as the Atheroscle-
rosis Risk in Communities Study (Framingham, MA; Minne-
apolis, MN; and Forsythe County, NC).
In summary, we found that hepatic steatosis, a strong risk
factor for diabetes, is common in post-menopausal women,
and non-Hispanic white women had a higher prevalence
than African-American women upon ultrasound. Risk fac-
tors in African-American women are similar to those in non-
Hispanic white women and consist of greater age and
adiposity as well as lower HDL cholesterol. Lower SHBG is a
marker for hepatic steatosis apart from waist circumference,
metformin and thiazolidinedione use. Further studies regard-
ing the natural history of hepatic steatosis in these two
groups and the impact of therapies to reduce hepatic steatosis
by race/ethnicity are needed. Finally, further investigation
regarding the roles of SHBG and hepatic steatosis in
mediating glucose tolerance are needed in populations that
are racially and ethnically diverse.
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